Hematology

Macro B12 may explain persistently raised vitamin B12 levels and help avoid unnecessary bone marrow biopsy in patients with low suspicion of malignancy.

Across 40 trials, 4 1BB based CAR T therapy targeting CD19 delivered the strongest remission rates and lower neurotoxicity in relapsed B cell precursor acute lymphoblastic leukaemia.

Hepta refractory multiple myeloma is characterised by antigen loss, complex genomic alterations, and poor survival, with limited benefit from successive salvage therapies.

A second course of R CHOP achieved durable responses in late relapse diffuse large B cell lymphoma, especially in patients relapsing more than 5 years after diagnosis.

Biologically informed plasma p-tau217 cutoffs improve amyloid beta detection accuracy and cost efficiency, outperforming standard thresholds and highlighting subgroup specific strategies for clinical implementation.

Early morning cord blood transplantation was shown to reduce acute graft-versus-host disease severity and improve survival.

A personalised multipeptide T cell activator induced durable immune responses and showed an acceptable safety profile in patients with chronic lymphocytic leukaemia in a phase one trial.

Presented at EAHAD 2026 and awarded third best poster, this multicentre study demonstrates that product-specific calibration improves the accuracy of factor VIII activity measurement across assay platforms.